NAUT: nautilus.bio Market Price to Net Income Ratio

Symbol and logo of brand Nautilus Biotechnology, Inc. (NAUT)

Nautilus Biotechnology (NAUT) maintains high defensive barriers driven by exclusive patents for its AI protein analysis system and support from the scientific community under strict HIPAA compliance. The operating model relies on external consumables suppliers and cloud services for data processing. This chart reflects the market trend for the separate_pe metric as -5.30. Business development is proceeding organically through partnerships with universities and the IT sector without M&A transactions.

Nautilus Biotechnology (NAUT) Price to Earnings Ratio: for the period 07/04/2022 - 11/12/2026

Analytical breakdowns for Nautilus Biotechnology

- price and consensus price forecast:
Stock Price Nautilus Biotechnology Inc|NAUT - Consensus Target
- market capitalization information:
Market Value Nautilus Bio|NAUT - Enterprise Value
- book capitalization indicators:
Net Assets per Share Nautilus Biotechnology|NAUT - Company Book Value|Market Value to Book Value Ratio nautilus.bio|NAUT - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Nautilus Biotechnology|NAUT - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Nautilus Biotechnology Inc|NAUT - Company Total Debt|Debt to Net Assets Ratio Nautilus Bio|NAUT - Company Long-Term Debts|Company Short-Term Debt Nautilus Biotechnology|Interim Coverage Ratio nautilus.bio
- earnings and market multiples details:
NAUT - Company Net Income|Expected Net Profit Nautilus Biotechnology|NAUT - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Nautilus Biotechnology Inc|NAUT - PEG Multiple|Company Value to EBITDA Nautilus Bio|NAUT - Operating profit EBITDA|Net earnings per share for the last 12 months Nautilus Biotechnology|NAUT - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months nautilus.bio|NAUT - Earnings per share growth in current year|Projected earnings per share growth rate for next year Nautilus Biotechnology
General company analysis:nautilus.bio - NAUT
Core merchandise of nautilus.bio

The P/E ratio determines the cost of a single unit of profit, allowing an investor to assess the degree of overpayment for an asset through the ratio of market price to net income. By analyzing the annual P/E of the company, one can diagnose the investment risks of Nautilus Biotechnology (NAUT), whose capitalization relies on the prospects of developing innovative proteome analysis systems for the creation of high-tech pharmaceuticals.

Key competitors

P/E Multiple Tempus AI Inc|Price to Earnings Ratio QGEN (Qiagen)|Market Price to Net Income Ratio IONS|P/E Multiple RGEN (Repligen Corp.)|Business Payback Period Avidity Corp (RNA)|CRSP - Price to Earnings Ratio|WGS: Price to Earnings Ratio|RARE (Ultragenyx) - Price to Earnings Ratio|Beam Therapeutics Inc (BEAM) - P/E Multiple|Price to Earnings Ratio Sarepta Therapeutics Inc|Twist Bioscience Corp (TWST) - Business Payback Period|Price to Earnings Ratio TXG (10x Genomics, Inc.)|NTLA (intelliatx.com) - Company Value to Net Income|P/E Multiple STOK (Stoke Therapeutics, Inc.)|BioLife Solutions Inc - Price to Earnings Ratio|Wave Life Sciences Corp - P/E Multiple|Business Payback Period Maze Therapeutics Corp MAZE|Sionna Therapeutics Inc (SION) - Price to Earnings Ratio|Market Cap to Earnings primemedicine.com (PRME)|Price to Earnings Ratio TSHA|QURE (uniQure NV) - Market Price to Net Income Ratio|P/E Multiple MGTX|RGNX - Market Cap to Earnings|P/E Multiple SLDB (Solid Biosciences Inc.)|OCGN - Price to Earnings Ratio|PacBio - P/E Multiple|Company Value to Net Income BNTC (Benitec Biopharma Inc)|Design Pharma (DSGN) - Price to Earnings Ratio|Price to Earnings Multiple RCKT|Price to Earnings Ratio 4D Molecular Therapeutics|Market Cap to Earnings Lexeo LXEO|Price to Earnings Ratio Korro Bio, Inc. (KRRO)|Price to Earnings Ratio EDIT (Editas Medicine Inc)|Price to Earnings Ratio Silence Therapeutics Inc. SLN|ProQR (PRQR) - Market Cap to Earnings|Codexis Bio - P/E Multiple|Market Cap to Net Income Ratio sangamo.com (SGMO)|MGX (Metagenomi) - Price to Earnings Ratio|Market Cap to Earnings precisionbiosciences.com (DTIL)|Price to Earnings Ratio Generation Bio Co|Price to Earnings Multiple BOLD (Boundless Bio Inc)|P/E Multiple XCUR|P/E Multiple imunon.com (IMNN)|Phio Pharmaceuticals Corp. - Price to Earnings Ratio|P/E Multiple Mustang Bio Inc MBIO|RNAZ: Price to Earnings Ratio|Bionano Genomics, Inc. - Market Price to Net Income Ratio|APDN: P/E Multiple|Price to Earnings Multiple BLUE|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd|Price to Earnings Multiple OMGA (Omega Therapeutics Inc)|P/E Multiple OMIC|P/E Multiple Regulus (RGLS)|Price to Earnings Ratio Syros Pharmaceuticals SYRS|TBIO: Price to Earnings Multiple|TRACON Pharmaceuticals, Inc. - P/E Multiple|UBX - P/E Multiple